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1. INTRODUCTION 
 
Intranasal administration is an effective way to deliver drugs into the systemic 
circulation as an alternative to the oral and parenteral routes for some therapeutic agents 
(Fig. 1). Undoubtedly, the nasal administration of medicines has been widely used for the 
treatment of topical nasal conditions such as nasopharyngitis or allergic rhinitis for many 
years. The nasal pathway may circumvent the blood–brain barrier and allow centrally acting 
pharmacons a direct transport route to the central nervous system. Concerning systemic 
delivery, drugs can be rapidly absorbed through the nasal mucosa, resulting in a quick onset 
of action, and avoiding degradation in the gastrointestinal tract and first-pass metabolism in 
the liver. 
 
 
Fig. 1: Intranasal administration of drugs. The target for drug delivery can be the nasal 
mucosa, the central nervous system or the systemic blood circulation. 
 
During the formulation of a pharmaceutical dosage form intended for intranasal 
application, several factors should be taken into consideration. The poor solubility of a drug 
and its low rate of dissolution can lead to insufficient absorption or delayed therapeutical 
effect. Indeed the nasally administered pharmaceutical preparations will be cleared rapidly 
from the nasal cavity into the gastrointestinal tract by the mucociliary clearance system. 
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2. AIMS 
 
For the development of relevant strategies to overcome biological barriers (eg. nasal 
mucosa) and in order to screen the feasibility of drug nanoparticles, innovative excipients and 
novel pharmaceutical compositions for nasal delivery targeting the systemic blood circulation, 
in vitro permeability models are useful and relevant tools. 
The aim of my scientific work was to establish an in vitro investigational protocol for 
drugs intended to use in nasal delivery (Fig. 2). The application of cell-based assays as well as 
conventional investigational methods of pharmaceutical technology is crucial for 
understanding the toxicity and efficacy of an innovative pharmaceutical composition. 
 
 
Fig. 2: The steps of a nasal investigational protocol to screen innovative formulations 
(nanoparticles) and novel pharmaceutical excipients (permeation enhancers). 
 
The main steps of our experiments were the following: 
(i) preparation and characterisation of meloxicam nanoparticles by co-grinding 
(ii) optimization of the preparation process by factorial experiment design 
(iii) establishment of in vitro methods for studying permeability of drugs in nasal 
formulations 
(iv) optimization of a culture model of the nasal system using RPMI 2650 cells 
(v) screen of the toxicity and efficacy of drug nanoparticles and pharmaceutical excipients 
by in vitro methods 
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3. MATERIALS AND METHODS 
 
3.1. Preparation and characterization of meloxicam nanoparticles 
Meloxicam (MEL) was obtained from EGIS Ltd. (Hungary). The grinding additives, 
polyvinylpyrrolidone (PVP) K25 and C30 were purchased from BASF (Germany). 
Polyethylene glycol (PEG) 6000 and 20 000 were from Sigma–Aldrich Chemie GmbH 
(Germany). MEL and carriers were mixed and charged into the chamber of the planetary 
monomill (Fritsch Pulverisette 6, Fritsch GmbH, Germany). 
Determination of particle size was performed by scanning electron microscopic image 
analysis. Products were washed and centrifuged to separate the excipient from the MEL, so 
that individual MEL particles could be studied. The particle size and the surface morphology 
of the MEL particles were visualised by scanning electron microscopy (SEM). Samples were 
fixed onto a metallic stub with double-sided conductive tape (diameter 12 mm, Oxford 
Instruments, UK). Images were taken in secondary electron image mode on a Hitachi S-4700 
Type II instrument (Japan) at an acceleration voltage of 10 kV. 
MEL particle diameter distributions were obtained by analysing SEM images with the 
ImageJ software environment. Over 150 individual particle measurements were made in at 
least five different images in order to determine the particle size. 
The following variables were the parameters featuring in the optimization (Table 1). A 
full factorial design plan was created and carried out with the MEL particle size distribution 
defined as response factor. All calculations were performed by using Minitab 14 (Minitab 
Statistical Software, USA). 
 
Table 1 Compositions of different samples, parameters of optimization 
Meloxicam/ excipient ratio 1:0.5, 1:1, 1:2 
Excipients PVP–C30, PVP–K25, PEG 6000, PEG 20 000 
Revolutions per minute (rpm) 200, 300, 400 
 
3.2. Investigations of the optimized products 
The physical state of MEL in the different samples was evaluated by X-ray powder 
diffraction (XRPD) analysis. Diffraction patterns were analysed with a Miniflex II X-ray 
Diffractometer (Rigaku Co., Japan). 
The solubility of MEL was determined at physiological conditions (pH 7.4, 37 °C) by 
addition of an excess of the drug to the solvent, after which the mixture was stirred on a 
5 
 
magnetic stirrer for 8 h, and the content of dissolved drug was analysed (Unicam UV/vis 
spectrophotometer, Germany). The extent of dissolution of MEL was studied in 50 mL 
phosphate buffer (PBS) at physiological conditions with Pharmatest equipment (Germany) at 
a paddle speed of 100 rpm. 
 
3.3. Franz cell diffusion – In vitro permeability 
In vitro permeability studies were performed with a vertical Franz–diffusion cell system 
(Hanson Research, USA) containing six cells. The donor phase contained MEL in 1 mg/mL 
and sodium hyaluronate in 5 mg/mL concentration, which were placed on the synthetic 
membrane impregnated with isopropyl myristate. Experiments were performed at 37 °C water 
bath. At predefined time points, samples of 0.8 mL were taken from the acceptor phase by the 
autosampler (Hanson Research, USA) and were replaced with fresh receiving medium. 
 
3.4. Cell culture experiments 
RPMI 2650 (ATCC cat.no. CCL 30) cells were grown in Eagle’s minimal essential 
medium supplemented with 10% foetal bovine serum and gentamicin in a humidified 37 °C 
incubator with 5% CO2. The cells were seeded on culture dishes at a density of 
5×105 cells/cm2 and the medium was changed every 2 days. For the cell viability assays cells 
were passaged to 96-well plates, for immunohistochemistry and nucleus staining cells were 
cultured on glass coverslips. For permeability studies cells were cultured on Transwell filter 
inserts (polycarbonate membrane, Corning Costar Co., USA). All surfaces were coated with 
rat tail collagen before cell seeding. Cell growth and morphology were monitored using a 
Nikon Eclipse TE2000 microscope (Nikon, Japan). 
The culture model was optimised by testing the 24-h effect of retinoic acid (RA) in 
three different concentrations: 0.01, 100, 300 µg/mL. Hydrocortisone (HC) was examined at 
500 nM; 8-(4-chlorophenylthio) adenosine 3',5'-cyclic monophosphate sodium salt (CPT-
cAMP) at 250 µM in the presence of 17.5 µM 4-(3-butoxy-4-methoxybenzyl)-2-
imidazolidinone (RO20-1724, Calbiochem, Germany), a phosphodiesterase inhibitor. 
 
Electron microscopy 
RPMI 2650 cells grown on Transwell filter membrane were fixed. After washing with 
cacodylate buffer several times, the membranes of the culture inserts with the cells were 
removed from their support and placed into 24-well chamber slide and were postfixed in 
OsO4. Finally the membranes of the culture inserts with the cells were removed from their 
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support and embedded in Taab 812 (Taab, UK). Following polymerisation, ultrathin sections 
were cut perpendicularly for the membrane using a Leica UCT ultramicrotome (Leica 
Microsystems, UK) and examined using a Hitachi 7100 transmission electron microscope 
(Hitachi Ltd., Japan). Electron micrographs were made by Megaview II (lower resolution, 
Soft Imaging System, Germany). Brightness and contrast were adjusted if necessary using 
Adobe Photoshop CS3 (USA). 
 
Immunohistochemistry 
To stain for junctional proteins RPMI 2650 cells cultured on rat tail collagen coated glass 
coverslips were washed and fixed. After washing cells were blocked with bovine serum 
albumin and incubated with primary antibody anti–β–catenin (Invitrogen, USA). Incubation 
with secondary antibody Cy3–labeled anti-rabbit IgG and Hoechst dye 33342 to stain cell 
nuclei lasted for 1 h. Between and after incubations cells were washed. Coverslips were 
mounted in Gel Mount (Biomeda, USA) and staining was examined by Olympus Fluoview 
FV1000 confocal laser scanning microscope. 
 
Cytotoxicity assays 
Real-time cell electronic sensing (RT-CES) is a label-free technique for dynamic 
monitoring of living cells. The xCELLigence system (Roche, Switzerland) utilises an 
electronic readout called impedance to non-invasively quantify adherens cell proliferation and 
viability. A special 96-well E–plate (Roche, Hungary) contains microelectronic sensor arrays. 
Culture media was added to each well for background readings than cell suspension was 
dispensed at the density of 6×103 cells/well. The cells were kept in an incubator for 24 h and 
monitored every 5 min. The cell index at each time point was defined as (Rn–Rb)/15, where Rn 
is the cell–electrode impedance of the well when it contains cells and Rb is the background 
impedance of the well with the media alone. 
Lactate dehydrogenase (LDH) release, the indicator of cell membrane damage, was 
determined from culture supernatants by a commercially available kit (Cytotoxicity detection 
kit LDH, Roche, Switzerland). 
Living cells convert the yellow dye 3-(4,5-dimethyltiazol-2-yl)-2,5- diphenyltetrazolium 
bromide (MTT) to purple, insoluble formazan crystals. After treatments the cells were 
incubated with MTT solution in an incubator. The amount of formazan crystals was dissolved 
in dimethyl sulfoxide and determined with a microplate reader (Fluostar Optima, BMG 
Labtechnologies, Germany). 
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Viability and nuclear morphology of RPMI 2650 cells were confirmed by fluorescent 
staining. Bis-benzimide (Hoechst dye 33342) labels the nuclei of both viable and dead cells. 
Ethidium-homodimer-1 (Molecular Probes, USA) cannot pass through the plasma membrane 
of viable cells, therefore only stains dead cells. Cell layers grown on coverslips were treated 
with surfactants, then bis-benzimide and ethidium-homodimer-1 was added. At the end of 
incubation cells were fixed, washed, mounted, and analysed using a fluorescent microscope 
(Nikon Eclipse TE2000, Japan) and photographed by a Spot RT digital camera (Diagnostic 
Instruments, USA). 
 
Nasal epithelial permeability studies 
The flux of MEL and fluorescein isothiocyanate labeled dextran (FITC-dextran, mw: 4.4 kDa) 
across epithelial cell layers were determined in permeability assays. RPMI 2650 cells were 
seeded onto Transwell filter inserts and grown for 2 days than the RPMI 2650 cells were 
treated with RA and HC for 24 h. The inserts were transferred to 12-well plates containing 
1.5 mL Ringer–Hepes solution in the basolateral compartments. In apical chambers the 
culture medium was replaced by 500 μL formulations containing 1 mg/mL MEL prepared in 
Ringer–Hepes. In case of studying permeability enhancers the culture medium from the apical 
chambers was replaced by 500 μL Ringer–Hepes containing 100 µg/mL FITC-dextran and the 
selected concentrations of permeability enhancers. The plates were kept in an incubator for 
1 h on a rocking platform. After incubation the concentrations of the drug and the marker in 
samples from the basolateral compartments were determined and the apparent permeability 
coefficients (Papp) were calculated as described by Youdim et al. (Drug Discov Today 8, 997, 
2003). 
 
4. RESULTS AND DISCUSSION 
 
4.1. Preparation and characterization of meloxicam nanoparticles 
With PVP–C30, it was possible to decrease the average MEL particle size (dSEM) 
below 250 nm and the average SD below 50%. This was a significant improvement relative to 
the additive-free grinding result. The optimum co-grinding parameter set for PVP–C30 was a 
MEL to excipient ratio 1:1, and a rotation frequency of 400 rpm. 
 
Table 2 Optimized products 
Grinding excipient Drug to excipient ratio Rotation speed (rpm) dSEM±SD (nm) 
PVP–C30 1:1 400 140.4±69.2 
PEG 6000 1:2 400 173.8 ± 60.3 
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The crystallinity of MEL was decreased in the co-grinding process with PVP–C30; in 
the other optimized product, which contains PEG 6000 the crystallinity of MEL did not 
change significantly as compared to the physical mixture. The crystalline MEL was altered in 
the co-grinding process with the amorphous excipient, PVP–C30, leading to amorphous 
nanoparticles. With PEG 6000 as excipient, MEL nanocrystals were prepared and the 
crystallinity of MEL was proved by XRPD (Fig. 3). 
 
Fig. 3: X-ray powder diffraction spectra of the optimized products (1, 2), the physical 
mixtures of the components (4, 3) and meloxicam (5). 
 
4.2. Dissolution of meloxicam nanoparticles 
Amorphous MEL nanoparticles showed favourable dissolution properties at 
physiological conditions. In one hand the solubility of MEL elevated up to about 1 mg/mL 
(Fig. 4A), on the other hand the extent of dissolution also increased, complete dissolution of 
MEL was observed in 15 min (Fig. 4B). 
 
Fig. 4: (A) Solubility of meloxicam (MEL) in case of the physical mixture (MEL/PVP) and the 
co-ground product (nanoMEL/PVP) in phosphate buffer (pH 7.4, 37 °C). (B) The extent of 
dissolution of MEL in case of the physical mixture (MEL/PVP) and the co-ground product 
(nanoMEL/PVP) in phosphate buffer (pH 7.4, 37 °C). MEL/PVP, meloxicam and 
polyvinylpyrrolidone C30 mass ratio 1:1. 
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The cumulative amount of MEL that diffused through a synthetic membrane from the 
different pharmaceutical compositions was measured against time (Fig. 5). The diffusion from 
the composition containing MEL nanoparticles and sodium hyaluronate was quicker, 25% of 
MEL was released from the formulation containing MEL in nanonized form vs. 10% in case 
of the physical mixture in the first 2 h. 
 
 
 
Fig. 5: In vitro permeability of meloxicam through an artificial membrane in case of the 
physical mixture (MEL/PVP) and the coground product (nanoMEL/PVP) in phosphate buffer 
(pH 7.4, 37 °C). MEL/PVP, meloxicam and polyvinylpyrrolidone C30 mass ratio 1:1; HA, 
sodium hyaluronate (5 mg/mL). 
 
 
4.3. In vitro cell culture model of the nasal barrier 
Due to the importance of systemic nasal drug delivery there is a need for cell culture 
models of the nasal barrier for testing various compounds and pharmaceutical compositions. 
The properties of such in vitro systems need to be compared with in vivo circumstances. 
In our experiments RPMI 2650 cells grew as mono- or multilayers and reached 
confluence in liquid–liquid interface culture condition. The presence of intercellular junctions 
was confirmed by electron and immunofluorescent microscopy. Besides morphological 
investigations the functional properties of the nasal epithelial barrier such as resistance and 
paracellular permeability were also proved. 
 
10 
 
 
Fig. 6: Morphological characterisation of RPMI 2650 human nasal epithelial cell line. (A) 
Phase contrast microscopic image of the cells (bar: 25 µm) and (B) confocal microscopic 
image of β–catenin immunostaining (bar: 10 µm) show cobble-stone, epithelial morphology. 
(C) Electron microscopic image of RPMI 2650 cells where arrows indicate tight intercellular 
junctions (N, nucleus; M, mitochondrion; ER, endoplasmatic reticulum; TJ, tight junction; V, 
microvilli; bar: 250 nm). 
 
Advantages of the presented in vitro nasal system include simplicity of culture, 
reproducibility, suitability for permeability studies and RT-CES. RPMI 2650 cells model the 
respiratory zone of the human nasal epithelium which is the most important absorption 
surface for nasally administered drugs to the systemic circulation. The absence of cilia and 
air–liquid interface can be considered as limitations of this nasal model. The presented data 
support that RPMI 2650 cells can be successfully used to establish an in vitro model of the 
nasal barrier and to test toxicity and epithelial permeability. 
 
4.4. Permeability of meloxicam nanoparticles across the in vitro nasal barrier 
To test the biological effects of the MEL nanoparticles an in vitro cell culture model of 
the nasal barrier, human RPMI 2650 cells were used. Impedance measured by RT-CES non-
invasively quantifies adherens cell proliferation, viability and cell layer integrity. The RT-
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CES results indicated no sign of disruption in the integrity of the RPMI 2650 cell layers, 
which could be observed in the toxicity control group (Fig. 7A). 
 
 
Fig. 7: (A) Real-time cell microelecronic sensing measurement of cell viability and integrity 
of human RPMI 2650 nasal epithelial cells treated by vehicle and the co-ground product 
(nanoMEL/PVP). (B) Apparent permeability coefficients (Papp) of MEL in case of the physical 
mixture (MEL/PVP) and the co-ground product (nanoMEL/PVP) measured across human 
RPMI 2650 nasal epithelial cell layers. MEL/PVP, meloxicam and polyvinylpyrrolidone C30 
mass ratio 1:1; HA, sodium hyaluronate (5 mg/mL); TX-100, TritonX-100 (10 mg/mL). 
 
The flux of MEL through the human RPMI 2650 cell layers was significantly slower 
than in the case of the Franz cell diffusion model, reflecting the more complex nasal barrier 
model of the in vitro cell culture system. The permeability coefficient of MEL for the 
composition containing MEL nanoparticles and sodium hyaluronate was 1.2×10-5 cm/s vs. 
0.5×10-5 cm/s in case of the physical mixture (Fig. 7B). 
 
4.5. Effects of sucrose esters and reference surfactants on epithelial barrier integrity 
Sucrose esters elicited dose-dependent TEER changes (Fig. 8A–B). At 0.1 mg/mL 
concentrations both laurate and myristate sucrose esters led to a significant and transient 
TEER decrease, while 0.3 mg/mL and higher concentrations caused an irreversible drop of 
TEER. Tween 80 at 10 mg/mL dose also resulted in a significant TEER decrease, while the 
lower concentration, similarly to 1 and 10 mg/mL concentration of Cremophor RH40 did not 
cause changes as compared to control group. 
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Fig. 8: Kinetics of the changes in transepithelial resistance of RPMI 2650 cells after 
treatment with surfactants. Broken line at 0 minutes indicates the onset of treatment. Data are 
presented as mean, n=4. C, control; TEER, transepithelial electric resistance. 
 
By treating the confluent layers of RPMI 2650 epithelial cells with previously 
determined safe, non-toxic concentrations of various surfactants, permeability experiments 
with FITC-dextran, a hydrophilic paracellular marker with an average molecular weight of 
4.4 kDa, the size of a peptide were performed. Laurate sucrose ester increased significantly 
the permeability of RPMI 2650 cell layers in a concentration-dependent manner (Fig. 9A). 
After 1-h treatment with 0.1 mg/mL laurate sucrose ester the apparent permeability coefficient 
of FITC-dextran was increased by 50%. 
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Fig. 9: The effect of non-toxic doses (0.01, 0.03, 0.1 mg/mL) of laurate sucrose ester (A) and 
of excipients applied in the same concentration of 0.1 mg/mL (B) on the apparent 
permeability coefficients of FITC-dextran on confluent RPMI 2650 cell layers. a: significantly 
different as compared to control group, p<0.05. Data are presented as mean±SD, n=3. C, 
control; CR, Cremophor RH40; L; laurate surose ester; M, myristate sucrose ester; TW, 
Tween 80; Papp, apparent permeability coefficient. 
 
Comparing the effects of sucrose esters and the reference surfactants on the 
permeability for the marker molecule across epithelial cell layers, the same, non-toxic 
concentration of 0.1 mg/mL was chosen for all compounds. All excipients increased 
significantly the epithelial paracellular permeability; the largest increase was seen in case of 
laurate sucrose ester, the Papp values were elevated from 9.7×10
-6
 cm/s to 1.4×10-5 cm/s after 
1-h treatment (Fig. 9B). 
 
5. SUMMARY 
 
Novel sites of drug administration for systemic delivery and novel formulations offer 
numerous opportunities to develop innovative pharmaceutical compositions. The nasal 
pathway represents an alternative route for non-invasive systemic administration of drugs, 
although the nasal epithelium forms a restricting barrier. Nanonization of drugs is a great 
possibility to increase solubility and to augment permeability through mucosal barriers. 
Pharmaceutical excipients may help to increase the solubility of active agents and enhance the 
permeability of molecules with larger molecular mass like peptides via the modulation of the 
paracellular pathway. 
An in vitro investigational protocol have been established to produce, characterize and 
screen innovative pharmaceutical solutions, namely meloxicam drug nanoparticles and 
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sucrose esters, novel biodegradable non-ionic surface active excipients to enhance nasal drug 
delivery. Both conventional investigational methods of pharmaceutical technology and cell-
based assays have been used. 
Using meloxicam as a model drug and polyvinylpyrrolidone as an excipient 
nanoparticles have been successfully produced by a co-grinding process optimized in a 
factorial experimental design. The physicochemical properties of these amorphous drug 
nanoparticles were favourable as compared to physical mixture. Increased solubility, 
enhanced extent of dissolution and in vitro permeability were found which are crucial 
parameters for nasal delivery. A human nasal epithelial cell culture model was established, 
characterized and optimized by morphological and functional methods. This model based on 
RPMI 2650 cells was applied for toxicity and permeability measurements. Nanonization 
resulted in enhanced permeability for meloxicam across epithelial cell layers without cellular 
toxicity and damage to barrier integrity. Sucrose esters at low doses altered paracellular 
permeability for a peptide-sized marker molecule of nasal epithelial cells without toxic 
effects. 
The presented nasal investigational protocol may contribute to the development of new 
pharmaceutical compositions and better screening systems for nasal delivery of pharmacons. 
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